This is unpublished
CONCORD: Combination of Novel Therapies for CKD Comorbid Depression
Active Studies
Actively Enrolling
CKD
Pinned
Principal Investigator
Rajnish Mehrotra
Funding Agency
NIDDK
Status
Active
investigator
What is Concord?
This study is being done to find out whether treatment of major depression with the medication, Bupropion, Behavioral Activation Teletherapy (BAT), both, Clinical Management (CM) and/or placebo will improve depression, quality of life and overall functioning in CKD patients. The secondary purpose is to find out whether CKD patients will be able to tolerate these treatments.
WHO DO I Contact FOR MORE INFORMATION?
Clinical Research Coordinator
Carlyn Clark
E: cclark5@uw.edu
P: 206-7220-3834